Search
Temafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnIt was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three
Terdecamycin
go.drugbank.com/drugs/DB19720ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Terdecamycin is a antibiotic, produced by Streptomyces strain. Terdecamycin has a monoisotopic molecular weight of 585.31 Da.
Stallimycin
go.drugbank.com/drugs/DB20261ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Stallimycin is a antibiotic, produced by Streptomyces strain. Stallimycin has a monoisotopic molecular weight of 481.22 Da.
Steffimycin
go.drugbank.com/drugs/DB19922ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Steffimycin is a antibiotic, produced by Streptomyces strain. Steffimycin has a monoisotopic molecular weight of 574.17 Da.
Anthelmycin
go.drugbank.com/drugs/DB20238ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Anthelmycin is a antibiotic, produced by Streptomyces strain. Anthelmycin has a monoisotopic molecular weight of 583.23 Da.
Bluensomycin
go.drugbank.com/drugs/DB20923ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Bluensomycin is a antibiotic, produced by Streptomyces strain. Bluensomycin has a monoisotopic molecular weight of 585.25 Da.
Lydimycin
go.drugbank.com/drugs/DB21235ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Lydimycin is a antibiotic, produced by Streptomyces strain. Lydimycin has a monoisotopic molecular weight of 242.07 Da.
Bimoclomol
go.drugbank.com/drugs/DB06258ExperimentalBimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.
Spectinomycin
go.drugbank.com/drugs/DB00919ApprovedVet approvedWithdrawnAn antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.